

41. The method of claim 40, wherein the donor cell infusion and the pancreatic islet cell transplant both occur within a twelve hour time period.
42. The method of claim 40, wherein the state of mixed chimerism is such that a donor chimerism level in the recipient of at least 15% is achieved as determined by measurements taken from the recipient's peripheral blood samples.
43. The method of claim 40, further comprising administering a cell pretreatment from the donor to the recipient prior to the infusion of the donor cells.
44. The method of claim 43, further comprising administering an antilymphocyte serum within 48 hours after an end of the cell pretreatment.

Please add new claims 65-79 as follows:


65. The method of claim 40, wherein the donor is a clinical cadaver and the pancreatic islet cell transplant, conditioning treatment, and the infusion of the donor cells are completed within a single continuous forty-eight hour period of time.
66. The method of claim 40, wherein the conditioning treatment is accomplished such that an amount of granulocytes in the recipient's blood decreases by less than 30%.
67. The method of claim 40, wherein the donor cell infusion is performed after the pancreatic islet cell transplant.
68. The method of claim 40, further comprising pretreating the recipient with pretreatment cells from the donor prior to the infusion of the donor cells.


69. The method of claim 40, wherein the conditioning treatment is accomplished by administering at least one drug chosen from the group consisting of fludarabine phosphate, busulfan, and cyclophosphamide.

70. The method of claim 40, wherein administering the conditioning treatment is accomplished by administering at least one drug chosen from the group consisting of a purine nucleoside analog, deoxycoformycin, 2-chloro-2' deoxyadenosine, ifosamide, etoposide, mitoxantrone, doxorubicin, cisplatin, carboplatin, cytarabine, paclitaxel, nitrosoureas, melphalan, thiotepa, antilymphocyte serum, anti-thymocyte globulin, and anti-lymphocyte globulin.

71. The method of claim 40, wherein administering the immune blockade treatment is accomplished by administering at least one of the compounds selected from the group consisting of anti-CD40L, sirolimus, CTLA4Ig, LEA29Y, and compounds that inhibit the binding of B7 to CD28.

72. The method of claim 40, wherein the conditioning treatment is started less than six days prior to the infusion of the donor cells.

 73. The method of claim 40, wherein the conditioning treatment is started less than two days prior to the infusion of the donor cells.

 74. The method of claim 40, wherein the donor cell infusion is performed by administering bone marrow from the donor to the recipient.

75. The method of claim 40, wherein the donor cell infusion is performed by administering stem cells to the recipient.

76. The method of claim 75, wherein the donor cell infusion includes administering the stem cells to the recipient on more than one day.